IL-11 promotes the treatment efficacy of hematopoietic stem cell transplant therapy in aplastic anemia model mice through a NF-κB/microRNA-204/thrombopoietin regulatory axis

다국어 초록 (Multilingual Abstract)

Hematopoietic stem cell (HSC) transplantation could be of therapeutic value for aplastic anemia (AA) patients, and immunosuppressants may facilitate the efficiency of the procedure. As anti-inflammatory cytokine interleukin-11 (IL-11) has a thrombopoietic effect, its use in cases of chronic bone marrow failure, such as AA, has been proposed to induce HSC function.
However, the putative mechanisms that may support this process remain poorly defined. We found that decreased miR-204-5p levels were coincident with increased proliferation in mouse HSCs following exposure to IL-11 in vitro. Through inhibiting NF-кB activity, miR-204-5p repression was demonstrated to be a downstream effect of IL-11 signaling. miR-204-5p was shown to directly target thrombopoietin (TPO) via sequence-dependent 3′-UTR repression, indicating that this microRNA-dependent pathway could serve an essential role in supporting IL-11 functions in HSCs. Increased TPO expression in HSCs following IL-11 exposure could be mimicked or blocked by inhibiting or overexpressing miR-204-5p, respectively. Consistent with these in vitro findings, IL-11 promoted HSC engraftment in a mouse model of AA, an effect that was attenuated in cells overexpressing miR-204-5p. The reduction in miR-204-5p levels is an integral component of IL-11 signaling that may play an essential role in treating AA.

참고문헌 (Reference)

1 Griffiths-Jones S, "miRBase: microRNA sequences, targets and gene nomenclature" 34 : 140-144, 2006

2 Summers RW, "Trichuris suis therapy in Crohn's disease" 54 : 87-90, 2005

3 de Graaf CA, "Thrombopoietin and hematopoietic stem cells" 10 : 1582-1589, 2011

4 Obana M, "Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart" 303 : 569-577, 2012

5 Obana M, "Therapeutic activation of signal transducer and activator of transcription 3by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction" 121 : 684-691, 2010

6 Zeng Y, "The complex pathophysiology of acquired aplastic anaemia" 180 : 361-370, 2015

7 Morrison SJ, "The bone marrow niche for haematopoietic stem cells" 505 : 327-334, 2014

8 de Latour RP, "Th17immune responses contribute to the pathophysiology of aplastic anemia" 116 : 4175-4184, 2010

9 Frickhofen N, "Schrezenmeier HGerman Aplastic Anemia Study G, Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia" 101 : 1236-1242, 2003

10 Kurzrock R, "Pilot study of low-dose interleukin-11 in patients with bone marrow failure" 19 : 4165-4172, 2001

11 O'Connell RM, "Physiological and pathological roles for microRNAs in the immune system" 10 : 111-122, 2010

12 Galardi S, "NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells" 39 : 3892-3902, 2011

13 Ooi AG, "MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets" 107 : 21505-21510, 2010

14 Guo S, "MicroRNA miR-125a controls hematopoietic stem cell number" 107 : 14229-14234, 2010

15 Tsimberidou AM, "Low-dose interleukin-11 in patients with bone marrow failure : update of the MD Anderson Cancer Center experience" 16 : 139-145, 2005

16 Ying Z, "Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype" 73 : 990-999, 2013

17 Zeng W, "Limited heterogeneity of T cell receptor BV usage in aplastic anemia" 108 : 765-773, 2001

18 Ng YY, "Isolation of human and mouse hematopoietic stem cells" 506 : 13-21, 2009

19 Du X, "Interleukin-11: review of molecular, cell biology, and clinical use" 89 : 3897-3908, 1997

20 Yucel OO, "Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases" 35 : 365-370, 2008

21 Bozza M, "Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells" 21 : 21-30, 2001

22 Curti A, "Interleukin-11 induces Th2 polarization of human CD4(+)T cells" 97 : 2758-2763, 2001

23 Risitano AM, "In-vivo dominant immune responses in aplastic anaemia : molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing" 364 : 355-364, 2004

24 Hosokawa K, "Identification of novel microRNA signatures linked to acquired aplastic anemia" 100 : 1534-1545, 2015

25 Trepicchio WL, "IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB" 159 : 5661-5670, 1997

26 Howlett M, "IL-11 is a parietal cell cytokine that induces atrophic gastritis" 61 : 1398-1409, 2012

27 Zhan Y, "Hematopoietic stem cell transplant in mice by intrafemoral injection" 430 : 161-169, 2008

28 McSweeney PA, "Hematopoietic cell transplantation in older patients with hematologic malignancies : replacing high-dose cytotoxic therapy with graftversus-tumor effects" 97 : 3390-3400, 2001

29 Kordasti S, "Functional characterization of CD4+ T cells in aplastic anemia" 119 : 2033-2043, 2012

30 Sun YX, "Dysregulated miR34a/diacylglycerol kinase zeta interaction enhances T-cell activation in acquired aplastic anemia" 8 : 6142-6154, 2017

31 Honma K, "Dosedependent effects of recombinant human interleukin-11 on the systemic hemodynamic function and urination" 54 : 73-76, 2007

32 Solomou EE, "Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia" 110 : 1603-1606, 2007

33 Young NS, "Current concepts in the pathophysiology and treatment of aplastic anemia" 108 : 2509-2519, 2006

34 Young NS, "Current concepts in the pathophysiology and treatment of aplastic anemia" 2013 : 76-81, 2013

35 Boyer LA, "Core transcriptional regulatory circuitry in human embryonic stem cells" 122 : 947-956, 2005

36 Betel D, "Comprehensive modeling of microRNA targets predicts functional non-conserved and noncanonical sites" 11 : R90-, 2010

37 Rector K, "Comprehensive hematopoietic stem cell isolation methods" 976 : 1-15, 2013

38 Giannakoulas NC, "Clinical relevance of balance between type 1 and type 2immune responses of lymphocyte subpopulations in aplastic anaemia patients" 124 : 97-105, 2004

39 DeZern AE, "Clinical management of aplastic anemia" 4 : 221-230, 2011

40 Arieta Kuksin C, "CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia" 125 : 2087-2094, 2015

41 Lechman ER, "Attenuation of miR-126 activity expands HSC in vivo without exhaustion" 11 : 799-811, 2012

42 Zhao J, "Arsenic trioxide and microRNA-204display contrary effects on regulating adipogenic and osteogenic differentiation of mesenchymal stem cells in aplastic anemia" 46 : 885-893, 2014

43 Zhu F, "Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia" 32 : 197-, 2015

44 Hosokawa K, "A plasma microRNA signature as a biomarker for acquired aplastic anemia" 102 : 69-78, 2017

45 Lezama RV, "A model for the induction of aplastic anemia by subcutaneous administration of benzene in mice" 162 : 179-191, 2001